PART I . We are a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of innovative, highly differentiated oral medicines that address significant health problems and meaningfully improve patients lives. We are committed to advancing novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologie...
Q2 FY2026 — expected 2026-09-06
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-26 | 2025-12-31 | 0001193125-26-073395 | EDGAR | 104K words |
| 2025-02-27 | 2024-12-31 | 0000950170-25-028355 | EDGAR | — |
| 2024-02-22 | 2023-12-31 | 0000950170-24-018414 | EDGAR | — |
| 2023-02-23 | 2022-12-31 | 0000950170-23-003935 | EDGAR | — |
| 2022-02-24 | 2021-12-31 | 0000950170-22-001860 | EDGAR | — |
| 2021-03-11 | 2020-12-31 | 0001564590-21-012240 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-04 | 2025-09-30 | 0001193125-25-263550 | EDGAR | 70K words |
| 2025-08-11 | 2025-06-30 | 0000950170-25-106229 | EDGAR | — |
| 2025-05-09 | 2025-03-31 | 0000950170-25-067498 | EDGAR | — |
| 2024-10-31 | 2024-09-30 | 0000950170-24-119249 | EDGAR | — |
| 2024-08-07 | 2024-06-30 | 0000950170-24-092275 | EDGAR | — |
| 2024-05-02 | 2024-03-31 | 0000950170-24-051567 | EDGAR | — |
| 2023-11-02 | 2023-09-30 | 0000950170-23-057743 | EDGAR | — |
| 2023-08-03 | 2023-06-30 | 0000950170-23-037581 | EDGAR | — |
| 2023-05-04 | 2023-03-31 | 0000950170-23-017462 | EDGAR | — |
| 2022-11-03 | 2022-09-30 | 0000950170-22-021543 | EDGAR | — |
| 2022-08-09 | 2022-06-30 | 0000950170-22-015745 | EDGAR | — |
| 2022-05-03 | 2022-03-31 | 0000950170-22-006947 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-27 | 0001193125-26-129170 | EDGAR | 1K words |
| 2026-02-26 | 0001193125-26-073561 | EDGAR | — |
| 2026-02-26 | 0001193125-26-073386 | EDGAR | — |
| 2026-01-13 | 0001193125-26-011104 | EDGAR | — |
| 2025-12-10 | 0001193125-25-314422 | EDGAR | — |
| 2025-12-08 | 0001193125-25-310670 | EDGAR | — |
| 2025-12-08 | 0001193125-25-310572 | EDGAR | — |
| 2025-11-04 | 0001193125-25-263540 | EDGAR | — |
| 2025-09-03 | 0001193125-25-194481 | EDGAR | — |
| 2025-08-11 | 0000950170-25-106227 | EDGAR | — |
111 total filings indexed. 83 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001815442 |
| Ticker | KYMR |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.kymeratx.com |
| Listed | 2020-08-21 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report